ARTICLE | Clinical News
TTI-621: Ph I started
February 1, 2017 9:45 PM UTC
Trillium began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate single and multiple doses of 3 dose levels of intratumoral TTI-621 in about 54 patients....
BCIQ Company Profiles
BCIQ Target Profiles